Cytochrome P450 CYP2D6 genotypes: Association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 269-276

  Strange, Richard C ^a   Ellison, Tracy ^a   Fumiyo, Ichii Jones ^a   Bath, Joanna ^a   Hoban, Paul ^a   Lear, John T ^b   Smith, Andrew G ^b   Hutchinson, Peter E ^c   Osborne, Joy ^c   Bowers, Bill ^d   Jones, Peter W ^a   Fryer, Anthony A ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

CYP2D6; Genetic predisposition; Malignant melanoma; Melanocyte stimulating hormone receptor; Polymorphism

Indexed keywords

CYTOCHROME P450;

ADULT; AGED; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAIR COLOR; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

EID: 0032767989     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199906000-00001     Document Type: Article

References (27)

1. Barnhill RL, Fine JA, Roush GC, Berwick M, Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78:427-432.
2. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antig 1998; 52:67-73.
3. Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997; 6:1891-1897.
4. Boyle P, Maisonneuve P, Dore J-F. Epidemiology of malignant melanoma. Br Med Bull 1995; 51:523-547.
5. Frankel WN, Schork NJ, Who's afraid of epistasis? Nature Genet 1996; 14:371-375.
6. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249:838-843.
7. Ichii-Jones F, Lear JT, Heagerty AHM, Smith AG, Hutchinson PE, Osbourne J, et al. Susceptibility to malignant melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermat 1998; 111:218-221.
8. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Arch Dermatol 1996; 132:444-450.
9. Koppula SV, Robbins LS, Lu DS, Baack E, White CR, Swanson NA, Cone RD. Identification of common polymorphisms in the coding sequence of the human MSH receptor (MCIR) with possible biological effects. Hum Mutat 1997; 9:30-36.
10. Kricker A, Armstrong BK, Jones ME, Burton RC. Health, solar radiation and environmental change. Technical report no. 13. Lyon: IARC; 1993.
11. Lear JT, Heagerty AH, Smith A, Bowers B, Payne CR, Smith CA, et al. Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 1996; 17:1891-1896.
12. Lear JT, Tan BB, Smith AG, Jones PW, Heagerty AH, Strange RC, Fryer AA. A comparison of risk factors for malignant melanoma, squamous cell carcinoma and basal cell carcinoma in the UK. Int J Clin Pract 1998; 52:145-149.
13. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
14. Morton D, Davtyen D, Wanek L, Foshag L, Cochran A. Multivariate analysis of the relationship between survival and microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993; 71:3737-3743.
15. Rannug A, Alexandrie A-K, Persson I, Ingelman-Sundberg M. Genetic polymorphism of cytochromes 1A1, 2D6 and 2E1; Regulation and toxicological significance. J Occup Environ Med 1995; 37:25-36.
16. Rees JL, Healy E. Melanocortin receptors, red hair, and skin cancer [Symposium Proceedings]. J Invest Dermat 1997; 2:94-98.
17. Rivers JK. Melanoma, Lancet 1996; 347:803-806.
18. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25:27-65.
19. Spencer JPE, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS Lett 1994; 353:246-250.
20. Sturm RA, Box NF, Ramsay M. Human pigmentation genetics: the difference is only skin deep. Bioassays 1998; 20:1-11.
21. Suzuki I, Cone RD, Sungbin IM, Nordlund J, Abdel-Malek ZA. Binding of melanotrophic hormones to the melanocortin receptor MCIR on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 1996; 137:1627-1633.
22. Valverde P, Healy E. Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nature Genet 1995; 11:328-30.
23. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, et al. The Asp84glu variant of the melanocortin-1 receptor (MCIR) is associated with melanoma. Hum Mol Genet 1996; 5:1663-1666, .
24. Wilhelmsen K, Mirel D, Marder K, Bernstein M, Naini A, Leal SM, et al. Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22qJ 3? Ann Neurol 1997; 41:531-536.
25. Wolf CR, Dale Smith CA, Gough AC, Moss JE, Vallis KA, Howard G, et al. Relationship between the debrisoquine polymorphism and cancer susceptibility. Carcinogenesis 1992; 13:1035-1038.
26. Worall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, et al. Susceptibility and outcome in oral cancer: Preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998; 8:433-139.
27. Xu X, Thornwall M, Lundin L-G, Chhajlani V. Val92met variant of the melanocyte stimulating hormone receptor gene. Nature Genet 1996; 14:384.